Lepu Bio-B (02157) rose more than 5%. As of press release, it rose 5.95% to HK$3.56, with a turnover of HK$3.336,800.
The Zhitong Finance App learned that Lepu Bio-B (02157) rose by more than 5%. As of press release, it had risen 5.95% to HK$3.56, with a turnover of HK$3.336,800.
According to the news, Lepu Biotech recently disclosed the 2023 annual results announcement. The group achieved revenue of 225 million yuan (RMB, same below) during the reporting period, a sharp increase of 1347.2% over the previous year. Gross profit was 197 million yuan, a year-on-year increase of 1352.6%. In addition, Lepu Biotech's CMG901 BD revenue and technical service revenue was 124 million yuan; as the company's first commercialized product, the PD-1 inhibitor prutelimab exceeded 100 million yuan in the first full year after marketing.